Last reviewed · How we verify
[18F]MK-6240, ~185 MBq — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[18F]MK-6240, ~185 MBq ([18F]MK-6240, ~185 MBq) — Merck Sharp & Dohme LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [18F]MK-6240, ~185 MBq TARGET | [18F]MK-6240, ~185 MBq | Merck Sharp & Dohme LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [18F]MK-6240, ~185 MBq CI watch — RSS
- [18F]MK-6240, ~185 MBq CI watch — Atom
- [18F]MK-6240, ~185 MBq CI watch — JSON
- [18F]MK-6240, ~185 MBq alone — RSS
Cite this brief
Drug Landscape (2026). [18F]MK-6240, ~185 MBq — Competitive Intelligence Brief. https://druglandscape.com/ci/18f-mk-6240-185-mbq. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab